New α7 nicotinic acetylcholine receptor radioligands available from Novandi Chemistry

Posted on okt 30, 2013

In cooperation with DanPET (Malmö, Sweden), Novandi Chemistry now can offer exclusive tritium labelled radioligands suitable for binding studies and in vitro visualization of the α7 nicotinic acetylcholine receptor (α7nAChR). The compounds [3H]NS14492 and [3H]NS10743 are patented, novel, small molecules with unique imaging properties. The compounds are α7 selective and have been shown to possess good imaging properties both in vitro and in vivo. Novandi Chemistry also now offers [3H]NS6784, which is an α7nAChR agonist with unique cognitive properties in an inhibitory avoidance (IA) model.

Small-molecule α7nAChR agonists are currently being developed as a potential treatment in various neuropsychiatric and neurodegenerative diseases such as schizophrenia and Alzheimer´s disease. Tritium labelled radioligands are valuable drug development tools and can be used in e.g. target engagement studies and preclinical validation of PET imaging protocols.

[3H]NS14492, [3H]NS10743 and [3H]NS6784 are sold exclusively by Novandi Chemistry and are available off the shelf. As such they can be delivered with short notice. They are delivered by courier service and are accompanied with a certificate of analysis. For more information on these compounds please visit our home page at http://www.novandi.se/catalog/.